Tag: non opioid pain patch market statistics

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Non-Opioid Pain Patch Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The non-opioid pain patch market has seen consistent growth in its size over recent years. It is projected to expand from $3.63 billion in 2025 to $3.79 billion in 2026, indicating a compound annual growth rate (CAGR) of 4.6%. This market’s historical growth can be attributed to concerns about opioid dependency, an increasing occurrence of musculoskeletal disorders, an expanding aging population, the development of retail pharmacy networks, and physicians’ inclination towards localized pain treatment.

The non-opioid pain patch market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $4.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.5%. This forecasted growth is driven by several factors, including the increasing occurrence of chronic pain, enhanced regulatory backing for non-opioid treatments, breakthroughs in transdermal drug delivery systems, rising patient understanding of non-addictive options, and the broadening of applications to include neuropathic pain. Key developments expected during this period involve a growing inclination towards non-addictive pain relief, increased use of topical and localized treatments, the proliferation of both over-the-counter and prescription hybrid patches, a greater need for chronic pain management solutions, and innovations in patch adherence and drug release duration.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=88978889&type=smp&name=Non-Opioid%20Pain%20Patch%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Non-Opioid Pain Patch Market Growth Backed By Core Demand Fundamentals

The increasing occurrence of chronic pain is projected to drive the expansion of the non-opioid pain patch market in the future. Chronic pain is defined as intense discomfort persisting over a prolonged duration or associated with an existing medical ailment. These patches, free from opioids, are utilized for alleviating mild to moderate discomfort, addressing conditions such as headaches, muscle pain, arthritis, backaches, and various other forms of pain. A concrete example from November 2024 highlights this trend: the Centers for Disease Control and Prevention, a national public health agency based in the US, reported that approximately 24.3% of adults had chronic pain in 2023. Of these, 8.5%, which is about one-third, experienced high-impact chronic pain, with a greater incidence observed in women compared to men. Consequently, the increasing prevalence of chronic pain is actively stimulating the non-opioid pain patch market.

Non-Opioid Pain Patch Market Segment Trends And Revenue Contributors

The non-opioid pain patch market covered in this report is segmented –

1) By Patch: Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, Other Patches

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

3) By Indication: Musculoskeletal Pain, Neuropathic Pain

Subsegments:

1) By Lidocaine Patches: 5% Lidocaine Patch, Other Concentrations

2) By Diclofenac Patches: 1.3% Diclofenac Patch, Other Concentrations

3) By Capsaicin Patches: 8% Capsaicin Patch, Other Concentrations

4) By Ketoprofen Patches: 5% Ketoprofen Patch, Other Concentrations

5) By Other Patches: Combination Patches, Herbal Extract Patches, Other Non-Opioid Patches

Non-Opioid Pain Patch Market Growth Trends Reshaping The Competitive Landscape

Leading companies in the non-opioid pain patch market are actively engaged in developing innovative products, including medicines based on genetically validated targets. This approach entails creating drugs that specifically address biological pathways directly linked to a disease, supported by strong genetic evidence, which enhances treatment effectiveness and reduces the likelihood of side effects. As an illustration, in February 2024, Latigo Biotherapeutics Inc., a US-based biotechnology company, launched LTG-001. This substance acts as a selective inhibitor of the Nav1.8 sodium channel, primarily found in peripheral nerve cells. By targeting this specific channel, LTG-001 aims to block pain signals where they originate, potentially offering effective pain relief without impacting the central nervous system. The outcomes of its Phase 1 clinical trial demonstrated that LTG-001 achieved a Tmax (time to maximum concentration) of roughly 1.5 hours, indicating a rapid commencement of pain relief. This feature holds significant importance for managing both acute and chronic pain. Additionally, LTG-001 is formulated for oral administration, providing patients with a convenient option compared to injectable or topical therapies, thereby enhancing patient compliance and ease of use.

Non-Opioid Pain Patch Market Competitive Landscape: Which Companies Lead The Industry?

Major companies operating in the non-opioid pain patch market are Hisamitsu Pharmaceutical Co. Inc., Teikoku Pharma USA Inc., Noven Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., Grünenthal GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Iroko Pharmaceuticals LLC, Scilex Pharmaceuticals Inc., Zosano Pharma Corporation, Adynxx Inc., BioElectronics Corporation, NeuroMetrix Inc., Virpax Pharmaceuticals Inc., Novartis AG, DURECT Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc.

View The Full Non-Opioid Pain Patch Market Report:

https://thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Non-Opioid Pain Patch Market Top Region: Where Does Most Revenue Come From?

North America was the largest region in the non-opioid pain patch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-opioid pain patch market report during the forecast period. The regions covered in the non-opioid pain patch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Non-Opioid Pain Patch Market Value Expansion And Long-Term Growth Outlook

The market for non-opioid pain patches has experienced consistent expansion over the past few years. Projections indicate an increase from $3.63 billion in 2025 to $3.79 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.6%. This historical growth has been driven by factors such as rising concerns about opioid dependence, a higher prevalence of musculoskeletal conditions, an expanding elderly demographic, broader retail pharmacy availability, and a tendency among physicians to favor localized pain management approaches.

The non-opioid pain patch industry is anticipated to experience significant expansion in the coming years. Its value is projected to reach $4.69 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.5%. This forecasted growth is driven by several factors, including a higher incidence of chronic pain conditions, stronger regulatory backing for non-opioid treatment options, progress in transdermal drug delivery systems, greater public awareness of addiction-free pain relief methods, and an extension of applications into neuropathic pain management. Key developments shaping this period encompass a growing preference for non-addictive pain control techniques, an increased use of topical and localized therapies, the introduction of hybrid patches available both over-the-counter and by prescription, heightened demand for solutions addressing chronic pain, and innovations in patch adhesion and the duration of drug release.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12230&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Non-Opioid Pain Patch Market Demand Drivers: What Is Fueling Industry Growth?

The growing incidence of chronic pain is anticipated to drive expansion in the non-opioid pain patch market moving forward. Chronic pain is defined as persistent, severe discomfort that lasts for an extended duration or occurs alongside another medical condition. Non-opioid pain patches are utilized to alleviate mild to moderate pain, addressing issues such as headaches, muscle aches, arthritis, backaches, and various other types of pain. As an example, in November 2024, the Centers for Disease Control and Prevention, a US-based national public health agency, reported that an estimated 24.3% of adults experienced chronic pain in 2023, with 8.5%—roughly one-third of those affected—experiencing high-impact chronic pain, and a higher prevalence observed among women compared to men. Consequently, the increasing prevalence of chronic pain is fueling growth in the non-opioid pain patch market.

Non-Opioid Pain Patch Market Segmentation: How Is The Market Structured Across Key Categories?

The non-opioid pain patch market covered in this report is segmented –

1) By Patch: Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, Other Patches

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

3) By Indication: Musculoskeletal Pain, Neuropathic Pain

Subsegments:

1) By Lidocaine Patches: 5% Lidocaine Patch, Other Concentrations

2) By Diclofenac Patches: 1.3% Diclofenac Patch, Other Concentrations

3) By Capsaicin Patches: 8% Capsaicin Patch, Other Concentrations

4) By Ketoprofen Patches: 5% Ketoprofen Patch, Other Concentrations

5) By Other Patches: Combination Patches, Herbal Extract Patches, Other Non-Opioid Patches

Non-Opioid Pain Patch Market Innovation Trends: Which Developments Are Transforming The Industry?

Major players in the non-opioid pain patch sector are focusing on the creation of advanced solutions, such as those based on genetically validated targets. This approach relies on designing drugs that act on biological mechanisms clearly implicated in illness, as supported by robust genetic data. Such a strategy improves therapeutic outcomes and minimizes the likelihood of adverse reactions. A relevant example is the launch of LTG-001 in February 2024 by Latigo Biotherapeutics Inc., a biotechnology firm from the United States. This drug works as a selective inhibitor of the Nav1.8 sodium channel, a protein mainly found in peripheral neurons. By specifically acting on this channel, LTG-001 seeks to intercept pain signals right where they originate, delivering substantial relief without impacting the central nervous system. Findings from Phase 1 clinical trials showed that LTG-001 reaches its maximum concentration (Tmax) in about 1.5 hours, indicating a quick initiation of pain relief. This property is highly valuable for controlling both sudden and persistent pain. Additionally, LTG-001 is intended to be taken orally, offering ease of use compared to injections or topical products, which could improve patient adherence and simplify daily management.

Non-Opioid Pain Patch Market Competitive Landscape And Leading Companies

Major companies operating in the non-opioid pain patch market are Hisamitsu Pharmaceutical Co. Inc., Teikoku Pharma USA Inc., Noven Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., Grünenthal GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Iroko Pharmaceuticals LLC, Scilex Pharmaceuticals Inc., Zosano Pharma Corporation, Adynxx Inc., BioElectronics Corporation, NeuroMetrix Inc., Virpax Pharmaceuticals Inc., Novartis AG, DURECT Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc.

Access The Complete Non-Opioid Pain Patch Market Report:

https://www.thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Non-Opioid Pain Patch Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the non-opioid pain patch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-opioid pain patch market report during the forecast period. The regions covered in the non-opioid pain patch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Non-Opioid Pain Patch Market Over The Forecast Period?

The non-opioid pain patch market has seen consistent growth in its size over recent years. This market is expected to expand from $3.63 billion in 2025 to $3.79 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.6%. Historically, this growth can be attributed to concerns about opioid dependency, an increasing incidence of musculoskeletal disorders, a growing aging population, the expansion of retail pharmacy networks, and physicians’ preference for localized pain treatment.

The non-opioid pain patch market is anticipated to experience robust expansion over the coming years. This market is projected to reach $4.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.5%. Key factors driving this growth during the forecast period include the increasing incidence of chronic pain, enhanced regulatory backing for non-opioid treatments, innovations in transdermal drug delivery technology, greater patient understanding of non-addictive treatment options, and the broadening of applications to include neuropathic pain. Significant trends expected during this period involve a heightened preference for non-addictive approaches to pain management, the increasing use of topical and localized treatments, the proliferation of over-the-counter and prescription hybrid patches, a greater need for solutions addressing chronic pain, and continuous innovation in both patch adhesion and the duration of drug delivery.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12230&type=smp

What Influential Factors Are Boosting The Non-Opioid Pain Patch Market Demand?

The increasing occurrence of chronic pain is projected to advance the expansion of the non-opioid pain patch market in the coming years. Chronic pain is defined as intense discomfort enduring for a prolonged duration or existing alongside another health ailment. Non-opioid pain patches are utilized for alleviating mild to moderate pain, addressing conditions such as headaches, muscle aches, arthritis, backaches, and other varieties of discomfort. As an example, a November 2024 report from the US-based Centers for Disease Control and Prevention, a national public health agency, estimated that in 2023, around 24.3% of adults dealt with chronic pain. Notably, 8.5% of these individuals, accounting for roughly one-third of those affected, reported high-impact chronic pain, with a higher prevalence observed in women compared to men. Thus, the escalating prevalence of chronic pain is driving the non-opioid pain patch market.

Which Segment Divisions Form The Structure Of The Non-Opioid Pain Patch Market?

The non-opioid pain patch market covered in this report is segmented –

1) By Patch: Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, Other Patches

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

3) By Indication: Musculoskeletal Pain, Neuropathic Pain

Subsegments:

1) By Lidocaine Patches: 5% Lidocaine Patch, Other Concentrations

2) By Diclofenac Patches: 1.3% Diclofenac Patch, Other Concentrations

3) By Capsaicin Patches: 8% Capsaicin Patch, Other Concentrations

4) By Ketoprofen Patches: 5% Ketoprofen Patch, Other Concentrations

5) By Other Patches: Combination Patches, Herbal Extract Patches, Other Non-Opioid Patches

What Trends Are Shaping The Non-Opioid Pain Patch Market Structure?

Leading companies in the non-opioid pain patch market are developing innovative products, including genetically validated targets medicine. This type of medicine involves creating drugs that target biological pathways directly linked to disease, supported by strong genetic evidence. Such an approach improves treatment effectiveness and reduces the risk of side effects. For instance, in February 2024, Latigo Biotherapeutics Inc., a US-based biotechnology company, launched LTG-001. This compound is a selective inhibitor of the Nav1.8 sodium channel, primarily expressed in peripheral nerve cells. By targeting this specific channel, LTG-001 aims to block pain signals at their source, potentially providing effective pain relief without affecting the central nervous system. Phase 1 clinical trial results indicated that LTG-001 has a Tmax (time to maximum concentration) of approximately 1.5 hours, suggesting a rapid onset of pain relief. This feature is particularly important for both acute and chronic pain management. LTG-001 is designed for oral administration, making it convenient for patients compared to injectable or topical treatments, a route of delivery that can enhance compliance and ease of use.

Who Are The Firms Contributing To The Non-Opioid Pain Patch Market Ecosystem?

Major companies operating in the non-opioid pain patch market are Hisamitsu Pharmaceutical Co. Inc., Teikoku Pharma USA Inc., Noven Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., Grünenthal GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Iroko Pharmaceuticals LLC, Scilex Pharmaceuticals Inc., Zosano Pharma Corporation, Adynxx Inc., BioElectronics Corporation, NeuroMetrix Inc., Virpax Pharmaceuticals Inc., Novartis AG, DURECT Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc.

Access The Complete Non-Opioid Pain Patch Market Report:

https://www.thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report

Which Region Commands The Largest Share Of The Non-Opioid Pain Patch Market?

North America was the largest region in the non-opioid pain patch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-opioid pain patch market report during the forecast period. The regions covered in the non-opioid pain patch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Non-Opioid Pain Patch Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=12230&type=smp

Browse Through More Reports Similar to the Global Non-Opioid Pain Patch Market 2026, By The Business Research Company

Non Opioid Pain Patch Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report

Pain Patch Market Report 2026

https://www.thebusinessresearchcompany.com/report/pain-patch-global-market-report

Pain Management Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pain-management-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Non-Opioid Pain Patch Market During The Forecast Period?

The non-opioid pain patch market has experienced consistent expansion in recent years. It is anticipated to expand from $3.63 billion in 2025 to $3.79 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.6%. This historical growth can be attributed to several factors such as opioid dependency concerns, an increasing incidence of musculoskeletal disorders, the growth in aging population, the expansion of retail pharmacy networks, and physician preference for localized pain treatment.

The non-opioid pain patch market is anticipated to experience robust growth in the upcoming years, with its size projected to reach $4.69 billion in 2030, reflecting a compound annual growth rate (CAGR) of 5.5%. This growth throughout the forecast period is driven by factors such as the increasing prevalence of chronic pain, strengthened regulatory support for non-opioid treatments, advancements in transdermal drug delivery technology, growing patient awareness regarding addiction-free therapies, and expansion into neuropathic pain indications. Key trends for the forecast period include a rising preference for non-addictive pain management, an increased adoption of topical and localized therapies, the expansion of over-the-counter and prescription hybrid patches, a greater demand for chronic pain management solutions, and innovation in patch adhesion and drug delivery duration.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12230&type=smp

Which Key Drivers Are Affecting The Non-Opioid Pain Patch Market Development?

An increase in chronic pain cases is projected to drive the expansion of the non-opioid pain patch market in the future. Chronic pain is defined as intense discomfort persisting over a prolonged duration or present alongside another health issue. These patches offer relief for mild to moderate pain, addressing conditions such as headaches, muscular discomfort, arthritis, backaches, and various other forms of pain. As an illustration, data from November 2024, provided by the Centers for Disease Control and Prevention, a national public health agency in the US, indicated that approximately 24.3% of adults in 2023 reported experiencing chronic pain. Of these, 8.5%—roughly one-third of the affected population—suffered from high-impact chronic pain, with a greater occurrence observed in women compared to men. Consequently, the growing incidence of chronic pain is a key factor boosting the non-opioid pain patch market.

What Segment Categories Shape The Non-Opioid Pain Patch Market Segment Landscape?

The non-opioid pain patch market covered in this report is segmented –

1) By Patch: Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, Other Patches

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

3) By Indication: Musculoskeletal Pain, Neuropathic Pain

Subsegments:

1) By Lidocaine Patches: 5% Lidocaine Patch, Other Concentrations

2) By Diclofenac Patches: 1.3% Diclofenac Patch, Other Concentrations

3) By Capsaicin Patches: 8% Capsaicin Patch, Other Concentrations

4) By Ketoprofen Patches: 5% Ketoprofen Patch, Other Concentrations

5) By Other Patches: Combination Patches, Herbal Extract Patches, Other Non-Opioid Patches

What Trends Are Transforming The Non-Opioid Pain Patch Market?

Leading companies within the non-opioid pain patch market are developing innovative products, including genetically validated targets medicine. This approach involves creating drugs that specifically target biological pathways directly connected to disease, grounded in robust genetic evidence. Such a method enhances the effectiveness of treatment and reduces the likelihood of side effects. For example, in February 2024, Latigo Biotherapeutics Inc., a US-based biotechnology company, introduced the LTG-001. This compound serves as a selective inhibitor of the Nav1.8 sodium channel, which is predominantly expressed in peripheral nerve cells. By targeting this particular channel, LTG-001 aims to block pain signals at their source, potentially delivering effective pain relief without affecting the central nervous system. Results from Phase 1 clinical trials indicated that LTG-001 has a Tmax (time to maximum concentration) of approximately 1.5 hours, suggesting a rapid commencement of pain relief. This attribute is especially significant for managing both acute and chronic pain. LTG-001 is designed for oral administration, offering greater convenience for patients compared to injectable or topical therapies. This delivery method can improve patient compliance and ease of use.

Who Are The Companies Operating Across The Non-Opioid Pain Patch Market Value Chain?

Major companies operating in the non-opioid pain patch market are Hisamitsu Pharmaceutical Co. Inc., Teikoku Pharma USA Inc., Noven Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., Grünenthal GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Iroko Pharmaceuticals LLC, Scilex Pharmaceuticals Inc., Zosano Pharma Corporation, Adynxx Inc., BioElectronics Corporation, NeuroMetrix Inc., Virpax Pharmaceuticals Inc., Novartis AG, DURECT Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc.

Get The Full Non-Opioid Pain Patch Market Report:

https://www.thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report

Which Region Leads The Non-Opioid Pain Patch Market In Terms Of Market Share?

North America was the largest region in the non-opioid pain patch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-opioid pain patch market report during the forecast period. The regions covered in the non-opioid pain patch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Non-Opioid Pain Patch Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report

Browse Through More Reports Similar to the Global Non-Opioid Pain Patch Market 2026, By The Business Research Company

Non Opioid Pain Patch Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report

Pain Patch Market Report 2026

https://www.thebusinessresearchcompany.com/report/pain-patch-global-market-report

Pain Management Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pain-management-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Non-Opioid Pain Patch Market During The Forecast Period 2026–2030?

The non-opioid pain patch market has experienced consistent growth in recent years. Its valuation is set to increase from $3.63 billion in 2025 to $3.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.6%. This historical growth can be largely attributed to mounting concerns regarding opioid dependency, a rising prevalence of musculoskeletal disorders, an expanding aging demographic, the widening scope of retail pharmacy networks, and the preference among physicians for localized pain management solutions.

The non-opioid pain patch market size is anticipated to experience robust expansion over the next few years. It is forecast to reach $4.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. This projected growth during the forecast period stems from factors such as an increasing prevalence of chronic pain, stronger regulatory endorsement for non-opioid treatments, progress in transdermal drug delivery technology, greater patient awareness regarding addiction-free alternatives, and the extension into neuropathic pain indications. Significant trends for the forecast period include a rising preference for non-addictive pain management, increasing adoption of topical and localized therapies, the expansion of over-the-counter and prescription hybrid patches, a heightened demand for chronic pain management solutions, and ongoing innovation in patch adhesion and drug delivery duration.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12230&type=smp

Which Major Factors Are Driving The Expansion Of The Non-Opioid Pain Patch Market?

The increasing incidence of chronic pain is anticipated to drive the future expansion of the non-opioid pain patch market. Chronic pain is defined as intense discomfort that persists for an extended duration or is linked to another health condition. Non-opioid pain patches are utilized for alleviating mild to moderate pain and for addressing conditions like headaches, muscle aches, arthritis, backaches, and other forms of pain. For instance, in November 2024, the Centers for Disease Control and Prevention, a US-based national public health agency, reported that an estimated 24.3% of adults experienced chronic pain in 2023. Of those affected, 8.5%, representing approximately one-third, reported high-impact chronic pain, with women showing a higher prevalence than men. As a result, the growing occurrence of chronic pain is propelling the non-opioid pain patch market.

What Market Segments Are Evaluated Within The Non-Opioid Pain Patch Market?

The non-opioid pain patch market covered in this report is segmented –

1) By Patch: Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, Other Patches

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

3) By Indication: Musculoskeletal Pain, Neuropathic Pain

Subsegments:

1) By Lidocaine Patches: 5% Lidocaine Patch, Other Concentrations

2) By Diclofenac Patches: 1.3% Diclofenac Patch, Other Concentrations

3) By Capsaicin Patches: 8% Capsaicin Patch, Other Concentrations

4) By Ketoprofen Patches: 5% Ketoprofen Patch, Other Concentrations

5) By Other Patches: Combination Patches, Herbal Extract Patches, Other Non-Opioid Patches

What Industry Trends Are Redefining The Non-Opioid Pain Patch Market?

Leading companies in the non-opioid pain patch market are developing innovative products, including genetically validated targets medicine. This approach involves creating drugs that target biological pathways directly linked to disease, relying on strong genetic evidence. Such a strategy enhances treatment effectiveness and reduces the risk of side effects. For instance, in February 2024, Latigo Biotherapeutics Inc., a US-based biotechnology company, launched the LTG-001. This compound is a selective inhibitor of the Nav1.8 sodium channel, primarily expressed in peripheral nerve cells. By targeting this specific channel, LTG-001 aims to block pain signals at their source, potentially offering effective pain relief without affecting the central nervous system. Phase 1 clinical trial results indicated that LTG-001 has a Tmax (time to maximum concentration) of approximately 1.5 hours, suggesting a rapid onset of pain relief. This feature is particularly important for managing both acute and chronic pain. Furthermore, LTG-001 is designed for oral administration, making it more convenient for patients compared to injectable or topical treatments. This route of delivery can enhance compliance and ease of use.

Who Are The Top Market Participants Influencing The Non-Opioid Pain Patch Market?

Major companies operating in the non-opioid pain patch market are Hisamitsu Pharmaceutical Co. Inc., Teikoku Pharma USA Inc., Noven Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., Grünenthal GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Iroko Pharmaceuticals LLC, Scilex Pharmaceuticals Inc., Zosano Pharma Corporation, Adynxx Inc., BioElectronics Corporation, NeuroMetrix Inc., Virpax Pharmaceuticals Inc., Novartis AG, DURECT Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc.

Read the full non-opioid pain patch market report here:

https://www.thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report

Which Region Currently Holds The Largest Share Of The Non-Opioid Pain Patch Market?

North America was the largest region in the non-opioid pain patch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-opioid pain patch market report during the forecast period. The regions covered in the non-opioid pain patch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Non-Opioid Pain Patch Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12230&type=smp

Browse Through More Reports Similar to the Global Non-Opioid Pain Patch Market 2026, By The Business Research Company

Non Opioid Pain Patch Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report

Pain Patch Market Report 2026

https://www.thebusinessresearchcompany.com/report/pain-patch-global-market-report

Pain Management Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pain-management-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the non-opioid pain patch market from 2026–2035 with trusted insights from The Business Research Company

How is the Non-Opioid Pain Patch Market size predicted to change over the forecast window of 2026–2035?

The non-opioid pain patch market size has experienced consistent growth in recent years. It is projected to expand from $3.63 billion in 2025 to $3.79 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.6%. Historically, this growth has been driven by factors such as worries about opioid dependency, a rising occurrence of musculoskeletal disorders, an expanding aging population, the broadening of retail pharmacy networks, and medical professionals’ preference for localized pain management.

The non-opioid pain patch market is projected to experience substantial expansion over the upcoming years. This market is set to reach $4.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.5%. Factors contributing to this anticipated growth include an increase in chronic pain cases, greater regulatory encouragement for non-opioid treatments, improvements in transdermal drug delivery methods, heightened patient understanding of non-addictive options, and the broader application of these patches for neuropathic pain. Key developments expected during this period involve a stronger inclination towards non-addictive pain relief, increasing acceptance of topical and localized treatments, the proliferation of over-the-counter and prescription hybrid patches, a greater need for solutions addressing chronic pain, and breakthroughs in patch adherence and the duration of drug delivery.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12230&type=smp

Which Drivers Are Contributing To The Expansion Of The Non-Opioid Pain Patch Market?

The increasing occurrence of chronic pain is anticipated to propel the growth of the non-opioid pain patch market going forward. Chronic pain is defined as severe discomfort that persists over an extended period or coexists with another medical condition. Non-opioid pain patches are utilized for alleviating mild to moderate pain, including headaches, muscle aches, arthritis, and backaches. As an illustration, in November 2024, the Centers for Disease Control and Prevention, a US-based national public health agency, reported that an estimated 24.3% of adults experienced chronic pain in 2023. Of these, 8.5% (roughly one-third of those affected) reported high-impact chronic pain, with a higher prevalence observed in women compared to men. This rising prevalence of chronic pain is, therefore, a key driver for the non-opioid pain patch market.

What Segment Categories Are Covered In The Non-Opioid Pain Patch Market?

The non-opioid pain patch market covered in this report is segmented –

1) By Patch: Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, Other Patches

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

3) By Indication: Musculoskeletal Pain, Neuropathic Pain

Subsegments:

1) By Lidocaine Patches: 5% Lidocaine Patch, Other Concentrations

2) By Diclofenac Patches: 1.3% Diclofenac Patch, Other Concentrations

3) By Capsaicin Patches: 8% Capsaicin Patch, Other Concentrations

4) By Ketoprofen Patches: 5% Ketoprofen Patch, Other Concentrations

5) By Other Patches: Combination Patches, Herbal Extract Patches, Other Non-Opioid Patches

What Long-Term Trends Are Expected To Shape The Future Of The Non-Opioid Pain Patch Market?

Leading companies in the non-opioid pain patch market are creating innovative products, including genetically validated targets medicine. This medicine type involves developing drugs that target biological pathways directly linked to disease, based on strong genetic evidence. This approach improves treatment effectiveness and lowers the risk of side effects. For instance, in February 2024, Latigo Biotherapeutics Inc., a US-based biotechnology company, launched the LTG-001. It acts as a selective inhibitor of the Nav1.8 sodium channel, predominantly expressed in peripheral nerve cells. By targeting this specific channel, LTG-001 aims to block pain signals at their origin, potentially delivering effective pain relief without impacting the central nervous system. Phase 1 clinical trial results showed that LTG-001 has a Tmax (time to maximum concentration) of approximately 1.5 hours, indicating a rapid onset of pain relief. This attribute is particularly crucial for managing both acute and chronic pain. LTG-001 is designed for oral administration, making it more convenient for patients compared to injectable or topical treatments. This delivery method can improve patient compliance and ease of use.

Which Major Industry Participants Are Leading The Non-Opioid Pain Patch Market Growth?

Major companies operating in the non-opioid pain patch market are Hisamitsu Pharmaceutical Co. Inc., Teikoku Pharma USA Inc., Noven Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., Grünenthal GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Iroko Pharmaceuticals LLC, Scilex Pharmaceuticals Inc., Zosano Pharma Corporation, Adynxx Inc., BioElectronics Corporation, NeuroMetrix Inc., Virpax Pharmaceuticals Inc., Novartis AG, DURECT Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Non-Opioid Pain Patch Market?

North America was the largest region in the non-opioid pain patch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-opioid pain patch market report during the forecast period. The regions covered in the non-opioid pain patch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Non-Opioid Pain Patch Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12230&type=smp

Browse Through More Reports Similar to the Global Non-Opioid Pain Patch Market 2026, By The Business Research Company

Non Opioid Pain Patch Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report

Pain Patch Market Report 2026

https://www.thebusinessresearchcompany.com/report/pain-patch-global-market-report

Pain Management Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pain-management-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model